ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
128.552,13
0,26%
S&P 500
6.114,63
-0,01%
US Dollar vs BRL
5,7143
0,01%
Bitcoin
96.267,06
0,51%
Brent Oil
75,185
0,07%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Centessa Pharmaceuticals PLC (CNTA)

  7. Centessa Pharmaceuticals PLC (CNTA) Notícias

CNTA

Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals PLC
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CNTA
DataHoraFonteTítuloCódigoCompanhia
14/02/202518:34Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:CNTACentessa Pharmaceuticals PLC
04/02/202518:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
03/02/202518:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
28/01/202510:00GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:CNTACentessa Pharmaceuticals PLC
08/01/202509:05GlobeNewswire Inc.Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical OfficerNASDAQ:CNTACentessa Pharmaceuticals PLC
08/01/202509:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
12/11/202409:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTACentessa Pharmaceuticals PLC
12/11/202409:00GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateNASDAQ:CNTACentessa Pharmaceuticals PLC
26/09/202407:00GlobeNewswire Inc.Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)NASDAQ:CNTACentessa Pharmaceuticals PLC
13/09/202417:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CNTACentessa Pharmaceuticals PLC
12/09/202423:34GlobeNewswire Inc.Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
11/09/202417:04GlobeNewswire Inc.Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
11/09/202417:01Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:CNTACentessa Pharmaceuticals PLC
10/09/202408:00GlobeNewswire Inc.Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy VolunteersNASDAQ:CNTACentessa Pharmaceuticals PLC
27/08/202409:00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)NASDAQ:CNTACentessa Pharmaceuticals PLC
21/08/202409:00GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
13/08/202408:00GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
10/06/202408:00GlobeNewswire Inc.Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business OfficerNASDAQ:CNTACentessa Pharmaceuticals PLC
13/05/202417:10GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
09/05/202409:01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CNTACentessa Pharmaceuticals PLC
09/05/202409:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNTACentessa Pharmaceuticals PLC
23/04/202422:36GlobeNewswire Inc.Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
23/04/202417:17GlobeNewswire Inc.Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
22/04/202408:00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
28/03/202417:28GlobeNewswire Inc.Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023NASDAQ:CNTACentessa Pharmaceuticals PLC
22/02/202410:00GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
09/02/202409:00GlobeNewswire Inc.Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia andNASDAQ:CNTACentessa Pharmaceuticals PLC
13/12/202310:00GlobeNewswire Inc.Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
10/12/202314:05GlobeNewswire Inc.Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of HemophiliaNASDAQ:CNTACentessa Pharmaceuticals PLC
27/11/202318:15GlobeNewswire Inc.Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsNASDAQ:CNTACentessa Pharmaceuticals PLC
 Apresentando as notícias mais relevantes sobre:NASDAQ:CNTA

Seu Histórico Recente

USOTC
HPST
Hempstract (PK)
COIN
ZWAPUSD
Zilswap
DOWI
DWDXOG
DJ Global Developed Ex U...
ASX
QUS
BetaShares
NYSE
MOD
Modine Manufacturing
LSE
0HWG
Chemours
DBI
I2SE
INXTRSP 500 EW 2D DL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios